The present invention provides an oligonucleotide comprising the sequence 5′;-GGAACAGTTCGTCCATGGC-3′; (SEQ ID NO:2) for use in the treatment of inflammatory bowel disease in a human subject, wherein individual doses of from 150mg to 350 mg of said oligonucleotide are administered to the subject on at least two separate occasions, wherein said separate occasions are 3 weeks apart.